Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00087451 | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) | PHASE1 | COMPLETED | 11 | — | — | Jul 1, 2004 | Nov 1, 2005 | Aug 19, 2015 | 4 | United States |
| Name | Type | Description |
|---|---|---|
| AP23573 | DRUG | ridaforolimus |
Inclusion Criteria (Patients must meet each of the following criteria to be eligible for participation in the trial): * Male or female patients ≥ 18 years of age * Patients must have a radiographically suspected progressive or recurrent primary malignant glioma (glioblastoma multiforme or gliosarco...